GHRP 6 (5mg x 10 Vials) and Ipamorelin (5mg x 10 Vials)
GHRP-6 & Ipamorelin Peptide Combination
Research peptides / unlicensed medicinal productsGrowth hormone\u2013releasing peptide combination (lyophilised vials)
Certifications
- No MHRA marketing authorisation identified for this peptide combination as a medicinal product in the UK.
- No specific CE marking as a medical device is indicated for this research peptide bundle.
- Marketed in the category of research chemicals/peptides, typically outside the scope of licensed medicines regulation when sold strictly for laboratory use.
- No MHRA marketing authorisation identified for this peptide combination as a medicinal product in the UK.
- No specific CE marking as a medical device is indicated for this research peptide bundle.
- Marketed in the category of research chemicals/peptides, typically outside the scope of licensed medicines regulation when sold strictly for laboratory use.
Growth hormone\u2013releasing peptide combination (lyophilised vials)
Description
This product is a peptide bundle consisting of GHRP-6 and Ipamorelin supplied as lyophilised powders in separate vials. Each bundle contains 10 vials of GHRP-6 (5 mg per vial) and 10 vials of Ipamorelin (5 mg per vial). It is marketed as a research peptide combination and is typically labelled for laboratory or research use only, not for human or veterinary administration.
Bnefits
- Provides two distinct growth hormone–releasing peptides (GHRP-6 and Ipamorelin) in a single bundle for experimental use.
- Standard 5 mg per vial presentation for each peptide simplifies concentration calculations in research settings.
- Ten vials of each peptide support repeated experiments or multi-sample protocols.
- Lyophilised (freeze-dried) format helps maintain peptide stability during storage and shipping prior to reconstitution.
- Intended for use in pre-clinical or in vitro research exploring growth hormone secretagogue pathways (not for clinical or human use).
Indications
- Sold and labelled as research peptides for laboratory investigation only.
- Not indicated as a licensed treatment for any human or veterinary medical condition.
- Any clinical, performance-enhancement or aesthetic use would be outside authorised medicinal frameworks and may be unsafe or illegal.
Composition
- GHRP-6 peptide (Growth Hormone Releasing Peptide-6) – 5 mg per lyophilised vial (10 vials in the bundle).
- Ipamorelin peptide – 5 mg per lyophilised vial (10 vials in the bundle).
- Lyophilised (freeze-dried) peptide powder in vials; any excipients (e.g. mannitol or buffering agents) are not specified in the public listing.
Formulation
- Lyophilised peptide powders supplied in glass vials.
- Each GHRP-6 vial contains 5 mg peptide in dry form.
- Each Ipamorelin vial contains 5 mg peptide in dry form.
- Intended to be reconstituted with a suitable sterile diluent in research environments according to institutional protocols (not for injection into humans or animals).
Packaging
- 10 x 5 mg vials of GHRP-6 lyophilised peptide.
- 10 x 5 mg vials of Ipamorelin lyophilised peptide.
- Total of 20 vials supplied as a combination bundle.
- Vials packed in protective outer packaging suitable for transport; detailed inner packaging configuration is not specified.
- Typically labelled as research use only / not for human consumption.
Usage
- Intended for laboratory research use only; not approved for human or veterinary administration.
- Handling, reconstitution, storage and disposal must follow institutional guidelines for research chemicals and peptides.
- Do not self-administer or use clinically; there is no validated dosing, safety or quality assurance for medicinal use in humans.
- Researchers should consult institutional protocols and any supplier documentation for guidance on reconstitution volumes and handling.
- Use appropriate personal protective equipment and aseptic technique when preparing and handling peptide solutions in a lab setting.
Contraindications
- Not for human or veterinary use; self-administration or non-research use is contraindicated and potentially dangerous.
- Should not be used as a substitute for licensed medicines or under unsupervised conditions.
- Use outside controlled research environments is contraindicated in individuals with any medical condition or those taking other medications.
- Not to be used by pregnant or breastfeeding individuals, minors or any non-research subjects.
Adverse Effects
- No formal safety profile exists for this commercial product in humans, as it is sold for research use only.
- Non-research use (e.g. self-injection) may pose serious, unpredictable risks such as endocrine disruption, cardiovascular strain, metabolic disturbances, local injection reactions or infection.
- Products in the research peptide market may be mislabelled, contaminated or inaccurately dosed, further increasing risk if misused.
Storage Conditions
- Store vials in a cool, dry place according to any temperature instructions on the packaging or labels.
- Keep protected from direct light and moisture.
- If recommended by the supplier, refrigerate or deep-freeze lyophilised peptides to preserve stability; follow any specific label guidance.
- Keep out of reach of unauthorised personnel, children and pets.
- Once reconstituted in a research setting, handle solutions using aseptic techniques and discard according to institutional chemical/biological waste policies.
Duration
Not applicable \u2013 this is a research peptide bundle and not an authorised medicinal product with a defined treatment course.
Onset
Not applicable \u2013 there is no approved therapeutic use or clinically defined onset of effect for this research-only product.
